Editas Medicine Files 8-K on Operations and Financials
Ticker: EDIT · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1650664
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
Editas Medicine dropped an 8-K on 10/22 detailing financials and operations.
AI Summary
On October 22, 2024, Editas Medicine, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also included Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This 8-K filing provides crucial updates on Editas Medicine's operational and financial status, which is essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on financial condition and operations, not a significant event like a merger or major regulatory update.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- October 22, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, Massachusetts (location) — Principal Executive Offices
- 11 Hurley Street (address) — Principal Executive Offices
FAQ
What specific financial information is being disclosed in this 8-K filing?
The 8-K filing indicates disclosure of 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not provided in the header.
When was this 8-K report filed?
The report was filed on October 22, 2024.
What is the primary business of Editas Medicine, Inc. according to the filing?
The filing categorizes Editas Medicine, Inc. under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
Where is Editas Medicine, Inc. headquartered?
The company's principal executive offices are located at 11 Hurley Street, Cambridge, Massachusetts 02141.
What is the SEC file number for Editas Medicine, Inc.?
The SEC file number for Editas Medicine, Inc. is 001-37687.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-10-22 07:04:58
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
- $265 million — of September 30, 2024 of approximately $265 million (the "Financial Information"). The Fina
Filing Documents
- edit-20241022.htm (8-K) — 28KB
- editasmedicinestrategicupd.htm (EX-99) — 33KB
- image_0a.jpg (GRAPHIC) — 10KB
- 0001650664-24-000114.txt ( ) — 204KB
- edit-20241022.xsd (EX-101.SCH) — 2KB
- edit-20241022_lab.xml (EX-101.LAB) — 21KB
- edit-20241022_pre.xml (EX-101.PRE) — 12KB
- edit-20241022_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 22, 2024, Editas Medicine, Inc. (the "Company") disclosed that it had preliminary unaudited cash, cash equivalents, and marketable securities as of September 30, 2024 of approximately $265 million (the "Financial Information"). The Financial Information contained in this Item 2.02 of this Current Report on Form 8-K is unaudited and preliminary, subject to the completion of the Company's third quarter financial closing procedures, and does not present all information necessary for an understanding of the Company's financial condition as of September 30, 2024 or the results of operations for the three or nine months ended September 30, 2024. The Financial Information may differ materially from the amounts that will be reflected in the Company's consolidated financial statements for the three and nine months ended September 30, 2024. The information contained in Item 2.02 in this Current Report on Form 8-K shall not be deemed "Filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 22, 2024, the Company issued a press release titled "Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept, and Strategic Update," a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "Filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on October 22, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: October 22, 2024 By: /s/ Erick Lucera Erick Lucera Chief Financial Officer